VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

Henderson, Nevada, May 14, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

Cameron Reynolds , President and Group Chief Executive Officer, said:

“We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.

“We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q ® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q ® Vet platform.

“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe’s leading cancer centers, on the reimbursement submission for Nu.Q ® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q ® in routine clinical practice, an exciting prospect which is core to Volition’s mission, using our tests to help save lives.

“We reported two new, potentially large, clinical use cases for our Nu.Q ® NETs assay beyond sepsis. In conjunction with the Mayo Clinic 1 , we demonstrated Nu.Q ® NETs’ potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa, 2 which affects about 1% of the world’s population. Both use cases have the potential to be large markets.

“We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.

“We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations.

“Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.”

Financial Highlights

• Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.

• Operating loss was down 3% for the quarter versus the comparable quarter in 2025.

• Net cash used in operating activities was $5.3 million.

• Receipts in the quarter included: $5.4 million in net proceeds from equity sales through our at-the-market facility, $1.9 million in net proceeds from issuance of a convertible note and warrant, and $1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.

• $5.4 million in net proceeds from equity sales through our at-the-market facility,

• $1.9 million in net proceeds from issuance of a convertible note and warrant, and

• $1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.

Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call

Date: Friday, May 15, 2026

Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13760656

Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2026, subsequent events and upcoming milestones.

A live audio webcast of the conference call will also be available on this link . In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.

• Navarro, Sergio M. et al, Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. SHOCK Journal, March 2026

• PrePrint

• Press Releases VolitionRx Announces Collaboration with Sysmex

• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share

• Tweet

• Share on Facebook

• Share

" * " indicates required fields